Portal de Periódicos da CAPES

Cerebral ischemia and neuroregeneration

2018; Medknow; Volume: 13; Issue: 3 Linguagem: Inglês

10.4103/1673-5374.228711

1876-7958

Hung-Wen Lin, Reggie Hui‐Chao Lee, MichelleH. H. Lee, CelesteY. C. Wu, Alexandre Couto e Silva, HarleeE Possoit, Tsung‐Han Hsieh, Alireza Minagar,

Adipose Tissue and Metabolism

Cerebral ischemia is one of the leading causes of morbidity and mortality worldwide. Although stroke (a form of cerebral ischemia)-related costs are expected to reach 240.67 billion dollars by 2030, options for treatment against cerebral ischemia/stroke are limited. All therapies except anti-thrombolytics (i.e., tissue plasminogen activator) and hypothermia have failed to reduce neuronal injury, neurological deficits, and mortality rates following cerebral ischemia, which suggests that development of novel therapies against stroke/cerebral ischemia are urgently needed. Here, we discuss the possible mechanism(s) underlying cerebral ischemia-induced brain injury, as well as current and future novel therapies (i.e., growth factors, nicotinamide adenine dinucleotide, melatonin, resveratrol, protein kinase C isozymes, pifithrin, hypothermia, fatty acids, sympathoplegic drugs, and stem cells) as it relates to cerebral ischemia.